Catalyst Dossier · compiled by CeliA 🧫
International Stem Cell CORP (ISCO)
Pharmaceutical Preparations · market cap $3M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-18
Conference
Pipeline
12
programs
Upcoming events
2
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2026-10-18Conferenceimp 2/10
- 2027-05-30 (est.)PDUFA · IBI343 (arcotatug tavatecan)imp 8/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| BOL-DP-o-04 + SCO | Phase 2 | Low Back Pain |
| dapivirine 4789 | Phase 2 | HIV-1 Infections |
| dapivirine (TMC120) vaginal gel | Phase 2 | HIV Infections |
| Lozanoc | Phase 2 | Neutropenia |
| GXCPC1 | Phase 2 | Knee Osteoarthritis |
| GXNPC1 | Phase 2 | Chronic Stroke |
| Ivermectin 0.5% Topical Application Lotion | Phase 3 | Head Lice |
| Dapivirine Vaginal Ring | Phase 2 | Human Immunodeficiency Virus |
| dapivirine | Phase 2 | HIV Infections |
| Dapivirine Vaginal Ring-004 | Phase 3 | HIV Prevention |
| Umbilical Cord Mesenchymal Stem Cell (UC-MSC) | Phase 2 | Retinitis Pigmentosa |
| Permethrin Cream, 5% | Phase 3 | Scabies |
Price & technical context
3-month
+94.1%
6-month
+120.0%
12-month
+153.8%
52-wk range
$0.12–$0.51
vs 50-day MA
+1.3%
vs 200-day MA
+64.5%
Realized vol
143.6%
Max drawdown
-50.0%
Daily closes through 2026-09-17. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ISCO (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 12 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.